Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score-Reference-Cited by-同舟云学术

Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score

Published:2023-05 Issue:5 Volume:83 Page:432-440
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Galsky Matthew D.,Bajorin Dean F.,Witjes Johannes Alfred,Gschwend Jürgen E.,Tomita Yoshihiko,Nasroulah Federico,Li Jun,Collette Sandra,Valderrama Begoña P.,Grimm Marc-Oliver,Appleman Leonard,Gravis Gwenaelle,Necchi Andrea,Ye Dingwei,Stenner Frank,Wind-Rotolo Megan,Zhang Joshua,Ünsal-Kaçmaz Keziban

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Urology

Reference14 articles.

1. PD-L1 expression as a predictive biomarker in cancer immunotherapy;Patel;Mol Cancer Ther,2015

2. Mechanisms regulating PD-L1 expression on tumor and immune cells;Chen;J Immunother Cancer,2019

3. PD-L1 as a biomarker of response to immune-checkpoint inhibitors;Doroshow;Nat Rev Clin Oncol,2021

4. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond;Zhu;J Immunother Cancer,2018

5. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project;Hirsch;J Thorac Oncol,2017

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States;Frontiers in Immunology;2024-09-13

2. Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021;Clinical Genitourinary Cancer;2024-06

3. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial;The Lancet Oncology;2024-06

4. C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study;Cancers;2024-04-28

5. Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer;JCO Precision Oncology;2024-04